The original success of the copyright undeniably revolutionized the medication landscape, but placing funds in companies primarily reliant on off-patent versions presents a complex picture. Despite early earnings were impressive, the end of patents and the emergence of less expensive alternatives have diminished market share. Consequently, a thorou